셀트리온

068270KOSPI기초 의약물질 제조업

57.2 / 100

Reference Date: 2026-06-10

Financial Score22.5 / 40

News Sentiment18.7 / 25

Momentum4.0 / 20

Disclosure12.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 16.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Celltrion is a global biotech company specializing in developing and commercializing biopharmaceuticals for autoimmune diseases and oncology, with 11 globally approved biosimilar products, including its first biosimilar, Remsima (CT-P13). It has expanded its global presence through strong market dominance in Europe and the U.S., and secured FDA approval for its subcutaneous infliximab formulation in 2023, aiming for 41.625 trillion KRW in sales by 2025.

Number of Employees

3,153people

Average Salary

108.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

36.42Industry Average 27.713.0Point

Higher than industry avg (caution)

PBR

2.17Industry Average 1.742.5Point

Higher than industry avg (caution)

ROE

5.91Industry Average -6.033.5Point

Well below industry avg

Debt Ratio

3.05Industry Average 6.626.5Point

Half of industry avg (excellent)

Trend 2023~20257.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲40.4% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲56.5% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 4.5% (improving, 3yr)

Detailed News Sentiment

54 totalPositive 38Neutral 13Negative 3Average Sentiment Score 74.6

Neutral
美, 우시앱텍·BGI ‘중국군사기업’ 지정…생물보안법 파장 커지나
미국의 중국 기업 지정이 글로벌 바이오 산업에 영향을 미칠 수 있으나, 직접적인 셀트리온 영향은 제한적이다.
Positive
샤페론, 월드 ADC·이중항체 서밋서 차세대 항체 플랫폼 '나노맙' 발...
셀트리온 관련 자회사 샤페론의 혁신적 항체 플랫폼 '나노맙' 기술 발표로 인해 긍정적인 시장 반응 예상.
Positive
SK "美 진출 지원" 삼성 "혁신기업 투자 확대"...생태계 확장 ...
SK의 미국 진출 지원과 삼성의 투자 확대로 셀트리온의 생태계 확장과 미래 성장 동력 확보에 긍정적 영향 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (12%, downtrend)

Current 170,000Won52-week high 248,50052-week low 159,000

1-month return0.0Point

1m -16.05% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

10 totalPositive 1Neutral 9Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-06-04
Neutral대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]2026-06-01
Neutral기업지배구조보고서공시2026-05-29
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-29
Neutral투자판단관련주요경영사항 (CTP6 SC(허쥬마 피하주사 제형) 한국 품목허가 신청)2026-05-28